Table 3. Summary of significant differences in the reporting of all grades and severe (CTCAE grade ≥3) all-causality adverse events over day 0–90 from first RE procedure in A. Patients with and without abnormal baseline laboratory parameters and B. In patients with at least grade 2 baseline laboratory parameters compared with those no or only mild changes in baseline laboratory parameters.
System organ, class | Baseline CTCAE grade ≥1 vs. Grade 0 | Baseline CTCAE grade ≥2 vs. Grade ≤1 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Bilirubin (n=37) | Albumin (n=199) | Alk Phos (n=351) | ALT (n=175) | AST (n=294) | Hemoglobin (n=238) | Albumin (n=72) | Alk Phos (n=99) | Hemoglobin (n=58) | ||
Total | Grade ≥3 | Grade ≥3 | Grade ≥3*, all grades* | Grade ≥3*, all grades | Grade ≥3* | |||||
Gastrointestinal | All grades | |||||||||
Abdominal pain | All grades | |||||||||
Nausea | All grades* | All grades | ||||||||
Abdominal distension | All grades | |||||||||
Intestinal obstruction | All grades | |||||||||
Flatulence | All grades | |||||||||
Constitutional | Grade ≥3 | Grade ≥3 | Grade ≥3*, all grades | Grade ≥3*, all grades | Grade ≥3 | |||||
Fatigue | Grade ≥3 | Grade ≥3 | Grade ≥3*, all grades | Grade ≥3* | ||||||
Fever | All grades* | All grades | All grades* | |||||||
Peripheral edema | Grade ≥3 | |||||||||
Psychiatric | All grades | All grades | ||||||||
Anorexia nervosa | All grades | |||||||||
Hepatobiliary | Grade ≥3*, all grades* | Grade ≥3 | All grades* | All grades | All grades* | Grade ≥3*, all grades* | Grade ≥3*, all grades* | |||
Hyperbilirubinemia | All grades* | Grade ≥3, all grades | All grades* | All grades* | All grades* | Grade ≥3*, all grades* | Grade ≥3*, all grades* | Grade ≥3 | ||
Ascites | All grades | |||||||||
REILD | Grade ≥3, all grades | |||||||||
Hepatic failure | Grade ≥3*, all grades | Grade ≥3, all grades | ||||||||
Respiratory | Grade ≥3 | |||||||||
Influenza | All grades |
*, P value <0.01. REILD, radioembolization-induced liver disease; CTCAEs, Common Terminology Criteria Adverse Events; AST, aspartate aminotransferase; ALT, alanine transaminase; Alk phosph, alkaline phosphatase;.